DCGI approves Bharat Biotech’s COVAXIN for Phase II/III clinical trial in 2-18 years
Delhi, May 13: The Drugs Controller General of India (DCGI) – the national regulator of the country, after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trial of Covaxin (COVID vaccine) in the age group 2 to 18 years, to its manufacturer Bharat […]
Continue Reading